Upregulated expression of miR-106a by DNA hypomethylation plays an oncogenic role in hepatocellular carcinoma

Tumor Biology

Volumn 36, Issue 4, 2015, Pages 3093-3100

  Yuan, Renshun ^a   Zhi, Qiaoming ^a   Zhao, Hong ^a   Han, Ye ^a   Gao, Ling ^a   Wang, Bin ^a   Kou, Zhongyang ^a   Guo, Zhaoji ^a   He, Songbing ^a   Xue, Xiaofeng ^a   Hu, Hao ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Hypomethylation; miR 106a; Oncogene

Indexed keywords

MICRORNA; MIRN106 MICRORNA, HUMAN; TUMOR MARKER;

APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICRORNAS; TUMOR MARKERS, BIOLOGICAL;

EID: 84936765265     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2945-2     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. doi:10.1002/ijc.25516.
3. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2. doi:10.1002/hep.24199.
4. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27. doi:10.1056/NEJMra1001683.
5. El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Ther Adv Gastroenterol. 2011;4(1):5–10. doi:10.1177/1756283X10385964.
6. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–55. doi:10.1016/S0140-6736(11)61347-0.
7. Nault JC, Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin Liver Dis. 2011;31(2):173–87. doi:10.1055/s-0031-1276646.
8. Nishida N, Goel A. Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics. 2011;12(2):130–7. doi:10.2174/138920211795564359.
9. Baer C, Claus R, Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res. 2013;73(2):473–7. doi:10.1158/0008-5472.CAN-12-3731.
10. Daniel FI, Cherubini K, Yurgel LS, de Figueiredo MA, Salum FG. The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer. 2011;117(4):677–87. doi:10.1002/cncr.25482.
11. Fabbri M, Calin GA. Epigenetics and miRNAs in human cancer. Adv Genet. 2010;70:87–99. doi:10.1016/B978-0-12-380866-0.60004-6.
12. Sato F, Tsuchiya S, Meltzer SJ, Shimizu K. MicroRNAs and epigenetics. FEBS J. 2011;278(10):1598–609. doi:10.1111/j.1742-4658.2011.08089.x.
13. Khare S, Zhang Q, Ibdah JA. Epigenetics of hepatocellular carcinoma: role of microRNA. World J Gastroenterol. 2013;19(33):5439–45. doi:10.3748/wjg.v19.i33.5439.
14. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
15. Jackson RJ, Standart N. How do microRNAs regulate gene expression? Sci STKE. 2007;2007(367):re1. doi:10.1126/stke.3672007re1.
16. Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12. doi:10.1016/j.ydbio.2006.08.028.
17. Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27–56. doi:10.1016/B978-0-12-380866-0.60002-2.
18. Chen X, Zhang L, Zhang T, Hao M, Zhang X, Zhang J, et al. Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC. Liver Int. 2013;33(3):476–86. doi:10.1111/liv.12097.
19. Dohi O, Yasui K, Gen Y, Takada H, Endo M, Tsuji K, et al. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol. 2013;42(2):411–8. doi:10.3892/ijo.2012.1724.
20. Long XR, He Y, Huang C, Li J. MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis. Int J Oncol. 2014;44(6):1915–22. doi:10.3892/ijo.2014.2373.
21. Xie K, Liu J, Chen J, Dong J, Ma H, Liu Y, et al. Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer. Gene. 2014;543(1):101–7. doi:10.1016/j.gene.2014.03.059.
22. Zhang PP, Wang XL, Zhao W, Qi B, Yang Q, Wan HY, et al. DNA methylation-mediated repression of miR-941 enhances lysine (K)-specific demethylase 6B expression in hepatoma cells. J Biol Chem. 2014;289(35):24724–35. doi:10.1074/jbc.M114.567818.
23. Wang F, Xue X, Wei J, An Y, Yao J, Cai H, et al. hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Br J Cancer. 2010;103(4):567–74. doi:10.1038/sj.bjc.6605724.
24. Ma L, Liu J, Liu L, Duan G, Wang Q, Xu Y, et al. Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes. Cancer Res. 2014;74(5):1452–62. doi:10.1158/0008-5472.CAN-13-2171.
25. Zhu M, Zhang N, He S, Lui Y, Lu G, Zhao L. MicroRNA-106a targets TIMP2 to regulate invasion and metastasis of gastric cancer. FEBS Lett. 2014;588(4):600–7. doi:10.1016/j.febslet.2013.12.028.
26. Li P, Xu Q, Zhang D, Li X, Han L, Lei J, et al. Upregulated miR-106a plays an oncogenic role in pancreatic cancer. FEBS Lett. 2014;588(5):705–12. doi:10.1016/j.febslet.2014.01.007.
27. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75(4):805–16.
28. Laranjeiro R, Tamai TK, Peyric E, Krusche P, Ott S, Whitmore D. Cyclin-dependent kinase inhibitor p20 controls circadian cell-cycle timing. Proc Natl Acad Sci U S A. 2013;110(17):6835–40. doi:10.1073/pnas.1217912110.
29. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis. 2010;30(1):17–25. doi:10.1055/s-0030-1247129.
30. Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol. 2013;87(2):227–47. doi:10.1007/s00204-012-0931-2.
31. Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol. 2014;28(5):843–53. doi:10.1016/j.bpg.2014.07.018.
32. Anwar SL, Lehmann U. DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. World J Gastroenterol. 2014;20(24):7894–913. doi:10.3748/wjg.v20.i24.7894.
33. Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, et al. miR-106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS. Mol Carcinog. 2013;52(8):634–46. doi:10.1002/mc.21899.
34. Catela Ivkovic T, Aralica G, Cacev T, Loncar B, Kapitanovic S. miR-106a overexpression and pRB downregulation in sporadic colorectal cancer. Exp Mol Pathol. 2013;94(1):148–54. doi:10.1016/j.yexmp.2012.11.002.
35. Huh JH, Kim TH, Kim K, Song JA, Jung YJ, Jeong JY, et al. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer. 2013;109(2):452–61. doi:10.1038/bjc.2013.305.
36. Dai DW, Lu Q, Wang LX, Zhao WY, Cao YQ, Li YN, et al. Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM. BMC Cancer. 2013;13:478. doi:10.1186/1471-2407-13-478.
37. Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, et al. An HNF4alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 2011;147(6):1233–47. doi:10.1016/j.cell.2011.10.043.
38. Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137(6):1005–17. doi:10.1016/j.cell.2009.04.021.